TheranosticTrials.org

Clinical Trial · NCT06224309

Preliminary Assessment of [18F]BL40 in PET/CT Scans

Overview

CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor function. There is a need for novel tracers to image CXCR4-expressing tumors for better detection, staging, and monitoring of aggressive cancers without the need for invasive biopsy procedures that may not always properly capture the extent of a patient's disease. This study looks to assess the safety and efficacy of a novel radiopharmaceutical known as 18F-BL40 through its use in a PET/CT scan. Participants will receive 2 PET/CT scans: 18F-BL40 and 18F-FDG as part of this study.

Sponsor

British Columbia Cancer Agency

Contacts

Ian Alberts (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06224309

Drug / Compound

BL40

Isotope(s):
Target(s):
  • CXCR4
Ligand Class: Small Molecules

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Participants with newly diagnosed or documented recurrent malignancy with one of the following cancers:
  • Diffuse large B-Cell lymphoma
  • Life expectancy ≥3 months
  • 1. Age ≥19 years

Exclusion

  • Unable to provide written consent
  • Medically unstable (e.g., acute illness, unstable vital signs)
  • 1. Pregnant or breast-feeding
  • Unable to lie supine for the duration of imaging
  • Exceeds safe weight limit of the PET/CT bed (204.5 kg) or unable to fit through the PET/CT bore (diameter 70 cm)